SCPX Stock Overview
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Scorpius Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.16 |
52 Week High | US$0.89 |
52 Week Low | US$0.14 |
Beta | 0.12 |
1 Month Change | -49.38% |
3 Month Change | -63.21% |
1 Year Change | -81.49% |
3 Year Change | -97.83% |
5 Year Change | -98.15% |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Dec 28Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Sep 02Heat Biologics names Anthony Manning as chief scientific advisor
May 10Heat Biologics EPS misses by $0.01, misses on revenue
May 05We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely
Apr 30Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Mar 07Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Jan 13Heat Biologics signs a licensing agreement; Appoints new CFO
Jan 06Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19
Dec 16Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year
Nov 20Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 02Shareholder Returns
SCPX | US Biotechs | US Market | |
---|---|---|---|
7D | 0.1% | 0.9% | 0.2% |
1Y | -81.5% | 11.0% | 28.1% |
Return vs Industry: SCPX underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: SCPX underperformed the US Market which returned 28.8% over the past year.
Price Volatility
SCPX volatility | |
---|---|
SCPX Average Weekly Movement | 17.5% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SCPX's share price has been volatile over the past 3 months.
Volatility Over Time: SCPX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 77 | Jeff Wolf | https://www.scorpiusbiologics.com |
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays.
Scorpius Holdings, Inc. Fundamentals Summary
SCPX fundamental statistics | |
---|---|
Market cap | US$5.90m |
Earnings (TTM) | -US$53.05m |
Revenue (TTM) | US$8.24m |
0.7x
P/S Ratio-0.1x
P/E RatioIs SCPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SCPX income statement (TTM) | |
---|---|
Revenue | US$8.24m |
Cost of Revenue | US$34.67m |
Gross Profit | -US$26.43m |
Other Expenses | US$26.62m |
Earnings | -US$53.05m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.47 |
Gross Margin | -320.76% |
Net Profit Margin | -643.86% |
Debt/Equity Ratio | 0% |
How did SCPX perform over the long term?
See historical performance and comparison